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Treatment failure in bioﬁlm-associated bacterial infections is an important healthcare issue.
In vitro studies and mouse models suggest that bacteria enter a slow-growing/non-growing
state that results in transient tolerance to antibiotics in the absence of a speciﬁc resistance
mechanism. However, little clinical conﬁrmation of antibiotic tolerant bacteria in patients
exists. In this study we investigate a Staphylococcus epidermidis pacemaker-associated
endocarditis, in a patient who developed a break-through bacteremia despite taking anti-
biotics to which the S. epidermidis isolate is fully susceptible in vitro. Characterization of the
clinical S. epidermidis isolates reveals in-host evolution over the 16-week infection period,
resulting in increased antibiotic tolerance of the entire population due to a prolonged lag time
until growth resumption and a reduced growth rate. Furthermore, we observe adaptation
towards an increased bioﬁlm formation capacity and genetic diversiﬁcation of the S. epi-
dermidis isolates within the patient.
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S ince the discovery of antibiotics, many bacterial infectionshave become treatable. However, antibiotic tolerance maylimit treatment efﬁciency, resulting in chronic and relapsing
infections, as found in bioﬁlm-associated infections. Bioﬁlms are
sessile communities of bacteria that are attached to biotic or
abiotic surfaces and are embedded in a matrix of extracellular
polymeric substances1. The environment within a bioﬁlm is
heterogeneous, with nutrient limitation in the lower layers
restricting growth. These non-growing or slow-growing bacteria
are protected from antibiotics targeting active cell growth
(reviewed in refs. 2,3).
In contrast to antibiotic-resistant bacteria, tolerant bacteria
remain fully susceptible to the antibiotic once they resume
growth. While the antibiotic minimum inhibitory concentration
(MIC) is the gold-standard metric to assess resistance, the
minimum duration to killing (MDK) metric has been proposed to
deﬁne tolerance2. The longer it takes to kill the bulk of a bacterial
population, the more tolerant this population is. This time-span
depends on the population’s cell growth rate and for growth-
arrested cells on their time to growth resumption. These growth
parameters are determined by both the environment and the
intrinsic properties of the strain. One can therefore distinguish
phenotypic tolerance from genotypic tolerance4. On the one
hand, the phenotypic tolerance is a transient state induced by a
speciﬁc environment, such as low pH, nutrient limitation, or
antibiotic challenge5. It often characterizes only a fraction of the
population, referred to as persister cells. On the other hand, the
genotypic tolerance involves mutations in the entire population.
Upon antibiotic exposure, tolerance of a bacterial population was
observed to evolve faster than resistance in vitro6,7, and this initial
adaptation has been described as an important step toward the
development of antibiotic resistance8,9.
Antibiotic tolerance has been studied in detail in vitro and in
mouse models (reviewed in refs. 2,10). The development of
affordable whole-genome sequencing technologies allowed the
analysis of in-host evolution in chronic infections, particularly of
Staphylococcus aureus, Escherichia coli, Enterococci ssp., and
Pseudomonas aeruginosa in cystic ﬁbrosis patients’ lungs
(reviewed in refs. 11,12). However, the adaptation toward
increased antibiotic tolerance has not been investigated in detail
within patients and has only been described for Enterococcus
faecium13. In the clinical setting, bacterial tolerance is still mainly
restricted to the endpoint observations of antibiotic treatment
failures caused by antibiotic-susceptible bacteria9.
Staphylococcus epidermidis is one of the most frequent causes
of medical implant-associated bioﬁlm infections causing ortho-
pedic-, pacemaker-, and prosthetic heart valve-associated infec-
tions14. Existing S. epidermidis studies using whole-genome
sequencing analyzed bacterial transmission in hospitals and
investigated typical hospital-associated clones from different
sources15–17. To our knowledge, none focused on in-host
evolution.
Here, we present in host evolution of a S. epidermidis strain
repeatedly isolated from a patient with a pacemaker-associated
endocarditis during an infection period of 16 weeks. The geno-
typic in host evolution of the S. epidermidis strains causing the
infection results in distinct phenotypes. The clinical isolates
obtained at later time points of the infection present increased
bioﬁlm formation, reduced growth rates, and prolonged times
until growth resumption when tested in vitro, resulting in
increased antibiotic tolerance.
Results
Clinical case. An afebrile 39-year-old man was admitted to the
University Hospital of Zurich due to a pacemaker pocket infec-
tion. This ﬁrst pacemaker was implanted 22 years ago because of
cardiac arrhythmia. A new pacemaker was then implanted on the
contralateral side 14 years later because of lead dysfunction of the
ﬁrst pacemaker. The leads of the ﬁrst inactive pacemaker were left
in situ since they could not be removed without causing damage
and thus were cut and capped. The batteries were replaced twice,
8 and 2 years prior to the infection.
Upon admission, the pocket of the inactive ﬁrst pacemaker was
debrided, and the electrodes were trimmed as they could not be
completely removed without open-heart surgery. Intraopera-
tively, turbid ﬂuid was found and sent for microbiological
analysis. S. epidermidis grew in multiple tissue samples, and,
accordingly, the empirical antibiotic treatment amoxicillin/
clavulanate was changed to intravenous vancomycin and
rifampicin (Fig. 1). Antimicrobial susceptibility testing revealed
a methicillin-susceptible S. epidermidis, only resistant to ampi-
cillin and erythromycin. Therefore, vancomycin treatment was
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Fig. 1 Overview of the clinical course, treatment, and S. epidermidis sampling. The antibiotic treatment scheme over the 16-week infection period. Surgical
interventions and time points of S. epidermidis recovery are indicated. PM Pacemaker, ST sequence type
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switched to ﬂucloxacillin and rifampicin treatment was contin-
ued. The local infection signiﬁcantly improved, and, after 12 days,
antibiotic treatment was switched to an oral regimen consisting of
rifampicin and ciproﬂoxacin and the patient was discharged from
the hospital.
Fourteen weeks later, the patient presented with fever and was
readmitted to the hospital. S. epidermidis grew in all four
inoculated blood culture bottles, after 29 h under aerobic
conditions and after 61 h under anaerobic conditions. A
pacemaker-associated endocarditis was diagnosed after an
echocardiography revealed two vegetations that were attached
to the ventricle and the right atrial electrode, respectively. The
empirically initiated systemic antibiotic treatment with dapto-
mycin was changed to intravenous ﬂucloxacillin, once methicillin
susceptibility was conﬁrmed and oral rifampicin was continued.
Blood cultures did not show any bacterial growth 2 days later.
Two weeks later, the pacemaker and all the leads were removed,
and an epicardial pacemaker was implanted during an open-heart
surgery. Despite the extensive antibiotic treatment, 70 S. epider-
midis colony-forming units (CFUs) per ml were cultivated after
sonication of the pacemaker aggregate and the leads. After
completing the antibiotic treatment, the patient fully recovered
and has been without an infection over the last 3 years as
documented by clinical, laboratory, and echocardiographic
follow-ups. An overview of the antibiotic treatment regimen
and the isolation time points of S. epidermidis is shown in Fig. 1.
Infection by susceptible strain under antibiotic treatment. In
this study, we characterized S. epidermidis clinical isolates
obtained over a 16-week period from a pacemaker pocket infec-
tion progressing to a pacemaker-associated endocarditis. Isolates
with different colony morphologies were detected. This resulted
in six distinct bacterial isolates obtained from the pocket site
infection at week 1 (isolates 1A–1F), one isolate obtained from
the blood culture (isolate 14G) at week 14 and thirteen isolates
from the explanted pacemaker aggregate and electrodes at week
16 (isolates 16H–16T, Table 1, Fig. 1). Multi-locus sequence
typing (MLST) and pulsed-ﬁeld gel electrophoresis (PFGE)
revealed that the majority of isolates belonged to the same
sequence type (ST) 378 and showed a very similar PFGE pattern
(Table 1, Supplementary Fig. 1). In addition to the ST378, ﬁve S.
epidermidis isolates obtained from the patient belonged to other
sequence types, four were ST88, and one was ST59. These other
sequence types were only detected at one time point during the
infection, at week 16. Using whole-genome sequencing, we aimed
to investigate their relation to the ST378 isolates. The ST378 is a
very rare sequence type, which so far has been isolated only once
as a commensal in Sweden in 2008 (www.pubmlst.org). All ST378
isolates obtained from the patient showed the same resistance
proﬁle; resistance to ampicillin/penicillin and erythromycin, and
susceptibility to all other antibiotics tested (including cipro-
ﬂoxacin, see MICs in Supplementary Table 1). However, devel-
opment of rifampicin resistance was observed in three out of the
eight ST378 isolates obtained at week 16 (16M, 16K, and 16H,
Table 1). The S. epidermidis isolate retrieved from the blood
cultures at week 14 was fully susceptible to ciproﬂoxacin and
rifampicin, the antibiotics that the patient was taking at that time.
Thus, the break-through bacteremia under ciproﬂoxacin and
rifampicin treatment indicated in vivo tolerance in the patient.
Since our focus was on the in-host evolution of the isolated S.
epidermidis strains as well as the characterization of the observed
in vivo tolerance of a susceptible S. epidermidis strain under
antibiotic treatment in a patient, we next performed detailed
phenotypic and genotypic analysis of the recovered ST378
isolates.
Phylogenomics reveal a high mutation rate and two clusters.
All clinical S. epidermidis isolates recovered, including all
sequence types (ST59, ST88, and ST378), were assessed by whole-
genome sequencing. This revealed three completely independent
strains that did not cluster together in a maximum-likelihood
tree, including all complete genomes available for S. epidermidis
on the National Center for Biotechnology Information database
(www.ncbi.nlm.nih.gov, Fig. 2a, Supplementary Table 3). This
conﬁrmed that the two other sequence types (ST59 and ST88)
recovered from the patient did not originate from the ST378 or
vice versa.
Detailed analysis of the ST378 sequencing data analysis
revealed an average total genome size of 2.44Mb. We identiﬁed
two plasmid replicons. The inferred plasmid 1 was present in all
Table 1 List of S. epidermidis isolates obtained from the patient over the infection period
Isolate ST Phylogenetic group Isolation week Isolation material Resistance proﬁle
1A 378 1 Week 1 Deep wound extract pocket site infection PEN, AMP, ERY
1B 378 1 Week 1 Deep wound extract pocket site infection PEN, AMP, ERY
1C 378 1 Week 1 Tissue pocket site infection PEN, AMP, ERY
1D 378 1 Week 1 Tissue pocket site infection PEN, AMP, ERY
1E 378 1 Week 1 Electrode (inactive PM) PEN, AMP, ERY
1F 378 1 Week 1 Electrode (inactive PM) PEN, AMP, ERY
14G 378 2 Week 14 Blood culture PEN, AMP, ERY
16H 378 2 Week 16 Electrode, n.s. PEN, AMP, ERY, RIF
16I 378 2 Week 16 Pacemaker aggregate PEN, AMP, ERY
16J 378 1 Week 16 Pacemaker aggregate PEN, AMP, ERY
16K 378 2 Week 16 Right ventricular electrode PEN, AMP, ERY, RIF
16L 378 2 Week 16 Right atrial electrode PEN, AMP, ERY
16M 378 2 Week 16 Right ventricular electrode PEN, AMP, ERY, RIF
16N 378 1 Week 16 Silicon caps of electrodes (inactive PM) PEN, AMP, ERY
16O 378 2 Week 16 Right atrial electrode PEN, AMP, ERY
16P 59 n.a. Week 16 Pacemaker aggregate PEN, AMP, ERY
16Q 88 n.a. Week 16 Silicon caps of electrodes (inactive PM) PEN, AMP
16R 88 n.a. Week 16 Electrode, n.s. PEN, AMP
16S 88 n.a. Week 16 Electrode, n.s. PEN, AMP
16T 88 n.a. Week 16 Electrode, n.s. PEN, AMP
n.a. not applicable, n.s. not speciﬁed, PEN penicillin, AMP ampicillin, ERY erythromycin, RIF rifampicin, PM pacemaker, ST sequence type
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isolates, had an estimated size of 26 kb and encoded the beta-
lactamase cassette blaIR1Z and the macrolide efﬂux pump msr(A)
matching the phenotypically observed resistance to ampicillin/
penicillin and erythromycin. Plasmid 2 was absent in two isolates,
1B and 16 N. It had an estimated size of 45 kb and encoded
mainly hypothetical proteins as well as two toxin–antitoxin
systems (YefM/YoeB and RelB/RelE). Moreover, in all ST378
isolates we identiﬁed a complete sequence of a STB20-like phage.
Investigation of known S. epidermidis virulence factors revealed
the absence of two important factors for bioﬁlm formation in all
ST378 isolates recovered18,19, the ica operon that encodes the
bioﬁlm polysaccharide intercellular adhesin (PIA) and bhp
encoding the homolog of the bioﬁlm-associated protein (Bap)
of S. aureus. However, all strains contained the following genes
relevant for bioﬁlm formation, sdrG, sdrH, embp, ebh, ebpS, aap,
sbpS, fmt, atlE, and sle1, indicating the potential of the strains to
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Fig. 2 Phylogenetic trees of the S. epidermidis isolates. a Midpoint-rooted maximum-likelihood tree based on the core-genes alignment of all the clinical
isolates (ST59 purple, ST88 green, ST378 blue/red), and all complete S. epidermidis reference genomes available on NCBI (black, Supplementary Table 2).
The scale bar indicates 0.002 SNPs per site. b Bayesian Evolutionary Analysis Sampling Trees (BEAST) phylogeny based on the ST378 isolates core gene
SNPs alignment. The branch length in this tree is determined by the sampling time point. The branch coloring illustrates the estimated mutation rate (SNPs
per site per year), whose range is indicated by the scale bar. Group I and group II isolates are indicated in blue and red, respectively. Dark red indicates the
clinical isolate retrieved from the blood culture. The symbols (blue star, square, circle and triangle and red star, square and circle) label subclusters within
the two main clusters. Denotations of these symbols can be found in the last column of Tables 2 and 3, to relate the mutations to the subcluster they were
found in
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form bioﬁlms, which we investigated in detail (Fig. 3). Regarding
the presence of toxins, all strains encoded beta hemolysin (hlb)
and a complete non-mutated set of phenol-soluble modulins
(PMS, α, β, β1a β1b, β2, β3, δ, and ε), including delta toxin (Hld,
PSM-γ). All isolates encoded a type III accessory gene regulator
(agr) system. The insertion element IS256 frequently found in
clinical S. epidermidis strains20 was absent in all ST378 isolates.
The gene content of the isolates regarding all known virulence
factors14 was generally identical, but the isolates differed in many
single-nucleotide polymorphisms (SNPs) and short insertions or
deletions (InDels) potentially affecting virulence and bioﬁlm
formation as discussed below. Altogether, this highlights that the
clinical ST378 isolate did not contain typical characteristics of
hospital-associated S. epidermidis strains, which are frequently
IS256, SCCmec, and ica positive and of agr type I and ST221,22.
A Bayesian Evolutionary Analysis Sampling Trees (BEAST)
phylogeny based on the alignment of the SNPs in the core genes
of the ST378 isolates revealed a sub-cluster of week 16 isolates (16
HIKLMO) and the bloodstream isolate (14G), which we named
group II (labeled in red, Fig. 2b). Week 1 isolates (1A–1E) plus
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Fig. 3 Bioﬁlm formation and hemolysis of the clinical ST378 isolates. a FEM pictures of the bioﬁlm formed on the patient’s electrode. Scale bar left 5 µm and
right 1 µm. b Quantitative in vitro bioﬁlm assay of ST378 isolates. Isolates were grown in TSB 0.5% glucose in 96-well plates, and the washed bioﬁlms were
quantiﬁed by OD600 measurement. Statistical signiﬁcance between the two groups was determined by Welch's t test (N= 60 t(46.40)=−10.513, P=
7.3 × 10-14). c Relative lysis of sheep blood erythrocytes by ST378 isolates indicated in percentages. The gray zone indicates the detection limit of 10% lysis
below which the values were not included. Statistical signiﬁcance between the two groups was determined by Welch's t test (N= 50 t(47.92)= 4.2857,
P= 8.7 × 10-5). Group I and group II isolates are indicated in blue and red, respectively. Dark red indicates the clinical isolate retrieved from the blood
culture. Averages with standard error of mean of at least three replicates are shown. ****P < 0.0001
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week 16 isolates 16N and 16J were referred to as group I (labeled
in blue, Fig. 2b). The isolate 16J falls between the two clusters, but
closer related to the group I isolates as visible in the maximum-
likelihood tree (Supplementary Fig. 2). The posterior node
probabilities indicated considerable uncertainty at the branching
event that gave rise to sample 1A (posterior probability 0.55) as
well as the placement of sample 16J (posterior probability 0.67).
However, the topology was robust under different model
assumptions in the Bayesian analysis and agreed with the
maximum-likelihood tree (Supplementary Fig. 2). Both week 16
isolates that clustered with the week 1 isolates, 16N and 16J,
showed a reduced estimated mutation rate of about 7 × 10−6
substitutions per site per year as compared with a more than 10-
fold higher mutation rate of about 3 × 10−5 for all other isolates
(Fig. 2b, branch coloring). The mutation rate was generally high,
but fell into the range of short-term evolutionary rate of 10−7–10−5
substitutions per site per year observed for other bacteria during
in-host evolution12. Isolates differed in pairwise comparison in up
to 34 SNPs, indicating diversiﬁcation of the S. epidermidis strain,
and differences even increased when InDels were included (see
below).
Mutations in regulatory and metabolic genes. As observed
previously in in-host adaptation studies, we found many muta-
tions in regulatory and metabolic genes. A complete list of all the
60 non-synonymous mutations (SNPs and InDels) differing
between the isolates is given in the Tables 2 and 3. Table 2 shows
the mutations characteristic of either all isolates, subclusters, or
single isolates from the group I phylogenetic cluster. Table 3
shows the mutations characteristic of either all isolates, sub-
clusters, or single isolates from the group II phylogenetic cluster.
Subclusters are labeled with colored symbols on the phylogenetic
tree (Fig. 2b) and denoted in the last column (“Phylogenetic
cluster”) in Tables 2 and 3. For example, the three rifampicin-
resistant isolates (16 H, 16 K, and 16M) belong to a subcluster
within group II, labeled with a red circle on the phylogenetic tree.
The mutations characteristic of this subcluster bear the “red
circle” denotation in the “Phylogenetic cluster” column. An
extended version of Tables 2 and 3, allowing a color-guided
visualization and showing the mutations localization in the S.
epidermidis RP62A reference genome can be found in the Sup-
plementary Information (Supplementary Table 3).
Commonly observed host adaptations of the close relative S.
aureus promoting persisting infections are mutations in the
global regulators (agr, sarA) and the alternative sigma factor B
likely resulting in decreased virulence, as well as in genes
associated with the stringent response12,23–26. For the clinical S.
epidermidis isolates recovered in this study, we observed
mutations in all of those genes, including two agrA mutants, a
sarA mutant, a mutation in rsbU, (a positive regulator of the
alternative sigma factor B), and mutations in the stringent
response genes relQ, rsh, and codY. This conﬁrms similarities in
in-host adaptation toward reduced virulence between S. aureus
and S. epidermidis, even though S. epidermidis is known to have a
much lower virulence potential14.
Furthermore, we found evidence of a general selection pressure
within the host since we observed multiple independent
mutations in the genes mqo, nrdl, and rpoB (Tables 2 and 3).
The latter, encoding the beta subunit of the RNA polymerase
(RNAP), is well known to evolve upon rifampicin exposure27. We
identiﬁed ﬁve independent mutations in rpoB, but only one was
detected in all three rifampicin-resistant strains, namely an
alanine insertion (Ala473_Asn474insAla). The other mutations
were found in the rifampicin-susceptible strains (Supplementary
Fig. 3, Supplementary Table 1).
In the following, we analyzed different phenotypes relevant for
the pacemaker-associated bioﬁlm infection to identify direct
phenotypic consequences of the in-host evolution.
In host adaptation toward increased bioﬁlm formation. The
presence of a bioﬁlm was conﬁrmed on the explanted pacemaker
electrode from the patient by ﬁeld emission scanning electron
microscopy (FEM) (Fig. 3a). Staphylococci embedded in an
extracellular matrix were visible together with some host cells. In
a next step, we analyzed the capacity of the different clinical
isolates to form bioﬁlm in vitro. Isolates from week 14 and 16
formed more robust bioﬁlms under in vitro conditions (Fig. 3b).
Isolates 16J and 16N showed less bioﬁlm formation and were
comparable with week 1 isolates (Fig. 3b), as reﬂected by the
phylogeny (group I, Fig. 2b, Supplementary Fig. 2). The two agrA
mutants, 16H and 16M, formed the thickest bioﬁlm. However,
the bioﬁlms formed by the agr mutants were more susceptible to
proteinase K and DNase I treatment as compared with the other
group II isolates (Supplementary Fig. 4).
As a surrogate marker for toxin production reﬂecting virulence,
we measured lysis of sheep blood erythrocytes (Fig. 3c) and
detected an adaptation toward decreased toxin production in
isolates recovered later during the infection period. Group I
isolates showed signiﬁcantly more hemolysis as compared with
group II isolates: on average (± standard deviation) 46 (± 15)%
and 28 (±13.5)%, respectively. Isolates 16J and 16K were outliers
from their respective groups.
Differences in growth characteristics. We analyzed the growth
characteristics of the isolates in the liquid medium (Fig. 4a). The
growth curve indicated that group I isolates reached a certain
OD600, e.g., an OD600 of 0.1, signiﬁcantly faster than group II
isolates (Fig. 4a, Supplementary Fig. 5a). This observation was
due to the delayed growth in a sub-cluster of three isolates within
group II (14G, 16L, and 16O). The minimal doubling time did not
signiﬁcantly differ between the two bacterial isolate groups
(Supplementary Fig. 5b).
The different growth dynamics of the isolates were also
reﬂected by their colony size at 24 h on agar plates (Fig. 4b).
Group II isolates showed on average a signiﬁcant smaller colony
size as compared with group I isolates. The three isolates within
group II, which had the slowest growth in liquid, also clustered in
their colony size. They showed the smallest colony sizes among
the group II isolates. These isolates (14G, 16L, and 16O) formed a
monophyletic cluster in the phylogeny (Fig. 2b, denoted by a red
star).
Prolonged lag time and slower growth. We and others reported
previously that a lag time can cause differences in colony size5,28.
To explore whether an increased lag time until growth resump-
tion was contributing to a reduced colony size, we assessed colony
growth kinetics of bacteria grown to stationary phase or under
bioﬁlm conditions in more detail. Three clinical isolates recovered
at the three different time points during the infection (1A, 14G,
and 16L) and reﬂecting the different colony sizes were assessed.
We observed a signiﬁcantly higher radial colony growth rate
for isolate 1A as compared with the isolates 14G and 16L (Fig. 5a,
b, insets). Thus, the variation in colony size is partly explained by
an altered growth rate. The week 14 and 16 isolates' (14G and
16L) colony growth curves showed a shift in time when compared
with week 1 isolate (1A) (Fig. 5a, b). This suggested that a lag time
contributed to the difference in colony size. To conﬁrm that this
observation reﬂected the growth dynamics at the microscopic
level, we monitored the time to single cells’ ﬁrst division of
stationary phase bacteria by time-lapse microscopy. We observed
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that the time for 80% of the population to resume growth differed
by > 1.5 h between isolate 1A and isolates 14G and 16L (averages ±
standard deviations: 2.3 ± 0.3 h, 4 ± 1.3 h, 3.8 ± 0.3 h, respectively)
(Fig. 5c).
In-host evolution resulted in antibiotic tolerance. To assess a
potential effect on antibiotic tolerance by the reduced growth rate
and increased lag time, we investigated killing efﬁciency by
highciproﬂoxacin concentrations. Ciproﬂoxacin time-kill curves
conﬁrmed an increase in bacterial survival for the late isolates
14G and 16L as compared with the early isolate 1A (Fig. 6b).
After 3 h of highdose ciproﬂoxacin exposure, 69% and 65% of the
late isolates 14G and 16L survived, respectively, as compared with
11% for the early isolate 1A. This means that the minimal time to
kill 90% of the population (MDK90) was 3 h for the early isolate
1A. Whereas MDK90 was between 3 and 6 h for the clinical iso-
lates 14G and 16 L. At 6 h, 7% and 5% of the population was still
alive, as compared with <1% for the early isolate 1A. To deter-
mine whether this difference in survival after 3 h ciproﬂoxacin
exposure reﬂected a global difference between group I as com-
pared with group II, we tested the survival of all 15 isolates after
Table 2 Non-synonymous SNPs and InDels found in the group I clinical ST378 S. epidermidis isolates
ID # Gene name/function Amino acid change Isolates Phylogenetic cluster
1 GraR, two-component response regulator Gly59Arg 1A, 1B, 1C, 1D, 1E, 1F, 16J,
16N
Group I
2 Sodium/di- and tricarboxylate cotransporter Ser161stop 1A, 1B, 1C, 1D, 1E, 1F, 16J,
16N
Group I
3 Cold-shock protein CspA Gly57fs 1A, 1B, 1C, 1D, 1E, 1F, 16J,
16N
Group I
4 RodA, rod shape-determining protein/FtsW, cell
division protein
Gly161Val 1A, 1B, 1C, 1D, 1E, 1F, 16J,
16N
Group I
5 PbuG, hypoxanthine/guanine permease Ser27Leu 1A, 1B, 1C, 1D, 1E, 1F, 16J,
16N
Group I
6 RpoB, DNA-directed RNA polymerase beta subunit Arg917Leu 1A, 1B, 1C, 1D, 1E, 1F, 16N
7 Sle1, autolysin, N-acetylmuramoyl-L-alanine amidase Val67Ala 1A
8 NrdI, ribonucleotide reduction protein Arg14stop 1A
9 SecDF, protein translocase subunit Ser621Asn 1A
10 Bicyclomycin-resistance protein TcaB/major myo-
inositol transporter IolT
Pro64Ala 1A
11 ClpC, ATP-dependent Clp protease ATP-binding
subunit
Arg12_Gln18del 1B, 1E, 16N Blue star
12 NrdI, ribonucleotide reduction protein Glu112fs 1B, 1E, 16N Blue star
13 Isocitrate dehydrogenase Val356Leu 1B, 1E, 16N Blue star
14 SufB, Fe-S cluster assembly protein Ala129Gly 1E
15 peptidase, U32 family large subunit [C1] Glu90Gln 1E
17 PrmA, ribosomal protein L11 methyltransferase Asp107Gly 1B, 16N Blue square
18 Sialic acid utilization regulator, RpiR family/MurR/RpiR
family transcriptional regulator
Val84Ile 1B, 16N Blue square
19 Two-component sensor kinase WalK Met428Thr 1B, 16N Blue square
20 SarA, Staphylococcal accessory regulator A Ala70Thr 16N
21 3’-to-5’ oligoribonuclease A Pro46fs 16N
22 acetate kinase Thr239Ala 16N
23 Mqo, malate:quinone oxidoreductase Ser431_Pro432_
Gly433_Ala434del
16N
24 Salicylate hydroxylase Ala290Gly 1C, 1D, 1F Blue circle
25 Manganese ABC transporter, inner membrane
permease protein SitD
Tyr243fs 1C
26 NrdI, ribonucleotide reduction protein Gln54stop 1C
27 YrrC, RecD-like DNA helicase, deoxyribonuclease Ile122Thr 1C
28 RpoC, DNA-directed RNA polymerase beta’ subunit Gly433Val 1D, 1F Blue triangle
29 RibU, riboﬂavin transporter Met1Val 1D, 1F Blue triangle
30 Iron-sulfur cluster assembly scaffold protein NifU Lys134Glu 1D
31 PurR, pur operon repressor Phe33Ser 1F
32 SrrB, respiratory response protein Ile13Ser 1F
33 RpoB, DNA-directed RNA polymerase beta subunit Gln137Pro 16J
34 Predicted RNA-binding protein, associated with RNAse
of E/G family
Val15fs 16J
35 general stress protein 13 (contains ribosomal protein S1
(RPS1) domain)
Thr31fs 16J
36 Mqo, malate:quinone oxidoreductase Arg375Trp 16J
37 PutP, proline/sodium symporter Leu353stop 1A, 1B, 1C, 1D, 1E, 1F, 16J,
16N, 14G, 16L,16O
Non-synonymous mutations characteristic of all isolates, subclusters or single isolates from the group I phylogenetic cluster (labeled in blue in Fig. 2). The numbering in the ﬁrst column is an
identiﬁcation number for each of the mutations reported (starting from 1 in Table 2, going up to 60 in Table 3). The isolates in which the mutations were found are given in the column “Isolates” and the
symbols denotations in the “Phylogenetic cluster” column refer to the colored symbols shown on the phylogenetic tree branches to characterize subclusters (Fig. 2b). An extended version of this table,
allowing a color-guided visualization and showing the mutations' localization in the S. epidermidis RP62A reference genome can be found in the Supplementary Information (Supplementary Table 3)
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ciproﬂoxacin challenge. We conﬁrmed a signiﬁcant difference
between group I and group II, with on average (± standard
deviation) 15 (±11)% and 61 (±19)%, respectively, of the bacterial
population surviving (Fig. 6c).
After 24 h, less than 0.01% of planktonic bacteria survived
ciproﬂoxacin treatment for all three strains (Fig. 6b, e,
Supplementary Fig. 6a). However, the survival under ciproﬂox-
acin drastically increased to 10–20% if bacteria were embedded in
a bioﬁlm (Fig. 6e). Survival of bacteria in pre-grown bioﬁlms was
only slightly further reduced to 5% when treated with a
combination of rifampicin and ciproﬂoxacin. There was no
difference observed between the early isolate and the late isolates
in the overall proportion of bacteria killed by ciproﬂoxacin and
the ciproﬂoxacin/rifampicin combination (Fig. 6e).
In addition to bacterial killing, we assessed the effect of
antibiotics on bioﬁlm integrity. Measuring the biomass by optical
density, we found more bioﬁlm remaining for 14G and 16L as
compared with 1A (Fig. 6f).
Discussion
In this study, we show in-host evolution of a ST378 S. epidermidis
strain, of which multiple spatially and temporally distinct isolates
were recovered from a patient with a bioﬁlm-associated pace-
maker endocarditis. In addition to the ST378 strain, we isolated
two other S. epidermidis strains of ST59 and ST88 from the same
patient, suggesting a polyclonal infection. Polyclonal infections
are not uncommon for S. epidermidis infections and were pre-
viously observed17,29. We cannot completely rule out that these
two other sequence types were contaminants of the isolation
process, as S. epidermidis is a common commensal of the human
skin and therefore prone to false positive detections.
We investigated in-host evolution of the ST378 isolates
recovered from three different time points during infection,
which only differed in a maximum of 34 SNPs. We performed
in vitro assays to assess phenotypic characteristics in order to
explore a link between the genetic mutations and phenotypes
observed. We found that most of the isolates recovered later
during the infection showed increased bioﬁlm formation,
decreased hemolysis, and an increased antibiotic tolerance,
reﬂected by their higher MDK90, as compared with the earlier
isolates.
Since antibiotic tolerance depends highly on a strain’s growth
characteristics, we monitored bacterial growth both at the mac-
roscopic and microscopic level. We found a signiﬁcantly slower
and delayed growth of the two late isolates 14G and 16L as
compared with the early isolate 1A, suggesting that both slower
and delayed growth were contributing to the increased antibiotic
tolerance phenotype of these isolates.
Considering the short time-span of 16 weeks, we observed a
high genetic diversity between the different isolates, which made
it difﬁcult to narrow down the phenotypic changes to a single
mutation. We can speculate that mutations in metabolic genes
like mqo could have an effect on growth. This gene was under
selection pressure within the host, reﬂected by different mutation
sites along with multiple branches of the phylogenetic tree.
Similarly, we report multiple mutations in rpoB, encoding the
beta subunit of the RNA polymerase (RNAP), and the target of
rifampicin. RpoB was previously shown to evolve quickly both
Table 3 Non-synonymous SNPs and InDels found in the group II clinical ST378 S. epidermidis isolates
ID # Gene name/function Amino acid change Isolates Phylogenetic cluster
38 Pta, phosphate acetyltransferase Asp245Tyr 14G, 16H,16I, 16K, 16L,
16M,16O
Group II
39 Penicillin-binding protein 1/Cell division protein FtsI Val605Leu 14G, 16H,16I, 16K, 16L,
16M,16O
Group II
40 RsbU, sigma factor B regulator Thr325Asn 14G, 16H,16I, 16K, 16L,
16M,16O
Group II
41 RNA-binding protein, conserved protein domain family EVE RNA
binding
Trp17Cys 14G, 16H,16I, 16K, 16L,
16M,16O
Group II
42 ArlR, two-component response regulator Leu51fs 14G, 16H,16I, 16K, 16L,
16M,16O
Group II
43 Mqo, malate:quinone oxidoreductase Arg132stop 14G, 16H,16I, 16K, 16L,
16M,16O
Group II
44 RpoB, DNA-directed RNA polymerase beta subunit Gly491_Gly492 insProGly 14G, 16L,16O Red star
45 MsrC, free methionine-(R)-sulfoxide reductase Gly64Asp 14G, 16L,16O Red star
46 Sat, sulfate adenylyltransferase Pro348Gln 14G, 16L,16O Red star
47 pyruvate dehydrogenase subunit beta/branched-chain alpha-
keto acid dehydrogenase E1
Glu201Lys 14G, 16L,16O Red star
48 MprF virulence factor, phosphatidylglycerol lysyltransferase Glu791_His792 insLeuGlu 16L
49 GTP-sensing transcriptional pleiotropic repressor CodY Glu254fs 16H, 16I, 16K, 16M Red square
50 glycerol-3-phosphate responsive antiterminator Gly129Ala 16H, 16I, 16K, 16M Red square
51 PrmA, ribosomal protein L11 methyltransferase Glu238Ala 16H, 16I, 16K, 16M Red square
52 RpoB, DNA-directed RNA polymerase beta subunit Gly492Val 16I
53 RelQ, (p)ppGpp synthetase Phe40fs 16I
54 RSH, (p)ppGpp synthase/hydrolase Leu533Phe 16H, 16K, 16M Red circle
55 RpoB, DNA-directed RNA polymerase beta subunit Ala473_Asn474 insAla 16H, 16K, 16M Red circle
56 HssR, heme response regulator Thr95Ala 16H, 16K, 16M Red circle
57 AgrA, accessory gene regulator protein A Glu42fs 16H
58 Hypothetical serine protease Arg78Ile 16H
59 AgrA, accessory gene regulator protein A Arg218Pro 16M
60 L-Cystine ABC transporter, periplasmic cystine-binding protein
TcyA
Thr45_Tyr46del 16M
Non-synonymous mutations characteristic of all isolates, subclusters or single isolates from the group II phylogenetic cluster (labeled in red in Fig. 2). The numbering in the ﬁrst column is an identiﬁcation
number for each of the mutations reported (starting from 1 in Table 2, going up to 60 in Table 3). The isolates in which the mutations were found are given in the column “Isolates” and the symbols
denotations in the “Phylogenetic cluster” column refer to the colored symbols shown on the phylogenetic tree branches to characterize subclusters (Fig. 2b). An extended version of this table, allowing a
color-guided visualization and showing the mutations' localization in the S. epidermidis RP62A reference genome, can be found in the Supplementary Information (Supplementary Table 3)
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in vitro and in vivo upon rifampicin exposure27. Mutations in
speciﬁc positions of the coding sequence are known to affect the
drug binding to the RNAP, leading to drug resistance. The spe-
ciﬁc insertion Ala473_Asn474insAla we detected in the three
resistant strains and which we assume is responsible for rifam-
picin resistance has not been described so far. However, the same
gene site was mutated (Ala473_Thr) in a rifampicin-resistant
clinical S. aureus isolate30.
While it is easy to deduce which mutation likely caused
rifampicin resistance, determining which mutations might have
affected tolerance is very difﬁcult. Whether the mutation in RsbU,
a positive regulator of the alternative sigma factor B, affects tol-
erance is difﬁcult to judge by the ﬁndings of previous studies.
Sigma B was shown to be crucial for SCV formation and per-
sisting infections of S. aureus23, but a rsbU mutation was shown
to have no effect on antibiotic killing in another study31. Trans-
poson mutagenesis studies further indicated that a limited
number of single genes affect antibiotic tolerance, such as
toxin–antitoxin systems and the stringent response pathway
(reviewed in refs. 2,3). However, the relevance of the stringent
response in antibiotic tolerance is under debate for S. aureus, the
closest relative of S. epidermidis24,32.
It seems likely that tolerance is caused by a combination of
different mutations. In this study, we observed mutations in genes
affecting the stringent response pathway (relQ, rsh, and codY).
However, two of the isolates we analyzed in more detail had a lag
in growth resumption and did not show any mutation in the
stringent response pathway. They had four mutations in common
in the following genes: rpoB, the methionine-sulfoxide reductase
msrC, the sulfate adenylyltransferase sat and the beta subunit of
the pyruvate dehydrogenase (mutations 44–47, “red star” phylo-
genetic cluster, Table 3). It remains unclear which mutation or
which combination was responsible for the increased lag time,
which we conﬁrmed in two different media (Fig. 5 and Supple-
mentary Fig. 8), as these speciﬁc mutations have not been
described before. The literature showed that mutations in rpoB
can affect the growth rate of S. epidermidis33, mutations in the
other three genes have not been described yet in S. epidermidis.
Thus, increased genotypic tolerance was likely due to both
mutations in the stringent response pathway as well as mutations
affecting the time to growth resumption. Mutant reconstruction
to link speciﬁc mutations to a distinct phenotype could not be
performed because the collected clinical S. epidermidis strains
were refractory to genetic manipulation.
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Fig. 4 Growth characteristics of ST378 isolates. a Growth curves of S. epidermidis isolates in the liquid TSB medium. The mean growth curve of three
replicates is shown. Statistical signiﬁcance of the time to reach OD 0.1 between the two groups was determined by Welch's t test (N= 46 t(29.96)=
−5.0064, P= 2.295 × 10-5). b Colony size for the different isolates after 24 h growth on sheep blood plates. Scatter dot plot with averages and standard
deviations of 89–182 colonies per isolate are shown. The gray zone corresponds to a colony radius < 100 µm, which was the detection limit of our setup.
Statistical signiﬁcance between the two groups was determined by Welch's t test (N= 1947 t(1587.8)=−19.634, P < 2 × 10−16). Group I and group II
isolates are indicated in blue and red, respectively. Dark red indicates the clinical isolate retrieved from the blood culture. The red star refers to the
monophyletic cluster formed by the three isolates with delayed growth curves and smallest colonies at 24 h. ****P < 0.0001
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The increased bioﬁlm formation by the isolates obtained later
during the infection (group II) could have been due to a frame-
shift mutation in the response regulator ArlR. Previous studies
showed that disruption of arlSR increased bioﬁlm formation in S.
aureus34,35. Contradictorily, reduction in bioﬁlm formation was
observed in an S. epidermidis study36. However, this reduction of
bioﬁlm formation in a S. epidermidis ArlSR mutant observed by
Wu et al. was ica-dependent; hence the ica-negative clinical iso-
lates might not be affected. In addition to the mutations speciﬁc
to the two groups of isolates also mutations in single isolates
could affect their capacity to form bioﬁlm. The two isolates of
group II forming the thickest bioﬁlm, 16H and 16M, contained
agrA mutations (mutations 57 and 59, Table 3), potentially
contributing to a more robust bioﬁlm phenotype as described in
previous studies. One study described increased bioﬁlm forma-
tion by an isogenic agr mutant as compared with wild-type strain
in a rabbit colonization model37. Another study reported that
RNAIII, the gene encoding for the effector molecule of the agr
system, was downregulated in clinical S. epidermidis isolates due
to mutations in agr38. This repression resulted not only in
increased bioﬁlm formation but also in increased cell death and
bioﬁlm dispersal, which ﬁnally promoted new bioﬁlm formation.
The mutation rate leading to this impressive diversiﬁcation of a
S. epidermidis strain within the medical implant associated bio-
ﬁlm was in the range of 10−5 substitutions per site per year,
which is at the upper limit described for other bacterial species12.
One study assessing transmission of S. epidermidis between
patients in a hospital showed no genetic differences39, which is in
contrast to the diversity at a single time point observed here.
However, a transmission bottle neck could be a potential expla-
nation for the limited genetic variability.
Reconstructing the theoretical time point when the infection
started, the BEAST analysis gave us an estimation of up to
4 weeks prior to the ﬁrst sampling date, which coincides with the
time when the patient presented with the erythema at the hos-
pital. As the patient’s last surgical intervention for battery
replacement was more than 2 years prior to this infection, it
seems unlikely that the pacemaker was contaminated at that time.
However, two isolates obtained at week 16 showed a reduced
mutation frequency. Isolate 16N was obtained from the silicon
caps of the wires of the inactive pacemaker located at the pocket
site, the same location as all week 1 isolates with which it clus-
tered in the phylogenetic tree. This suggests a potential niche
adaptation. However, isolate 16J was obtained from the same agar
plate of the sonicate of the active pacemaker aggregate as isolate
16I and the ST59 isolate. This highlights again the in-patient
diversity as isolates 16J and 16I differed in 22 SNPs and InDels.
Sequencing more colonies, including colonies that do not differ in
morphology would have given a more complete picture of the
infecting population and would have allowed a better inter-
pretation of the in-host evolution. Still, based on our observation,
Fig. 5 Macroscopic and microscopic analysis of the bacterial population’s
growth kinetics. a Colony growth curves of bacteria obtained from
stationary phase cultures and b bioﬁlms. The gray zone corresponds to a
colony radius < 100 µm, which is under the detection limit of the
macroscopic time-lapse setup. Small insert graphs show the distribution of
the radial colony growth rate (GR) in µm h−1 for the three isolates.
Statistical signiﬁcance between the three samples was determined by one
way ANOVA (For the stationary: N= 182, F(2,179)= 488.7, P < 2 × 10−16,
and Tukey’s post hoc test t14G-1A=−16.45, p14G-1A= 0, t16L-1A −12.47, p16L-
1A= 0/bioﬁlm: N= 237, F(2,234)= 311.8, P < 2 × 10-16 and Tukey’s post
hoc test t14G-1A=−11.69, p14G-1A= 0, t16L-1A=−10.05, p16L-1A= 0). c Time
to single cells’ ﬁrst division. Curves show averages of three replicates and
shaded areas depict standard deviation. The gray zone marks the period at
the beginning of the experiment where cell divisions could occur, but not be
observed. Group I and group II isolates are indicated in blue and red,
respectively. Dark red indicates the clinical isolate retrieved from the blood
culture. ****P < 0.0001
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the cutoff values for the determination of transmission have to be
chosen carefully if S. epidermidis bioﬁlm-associated infections are
involved.
The uneven mutation rate highlights that, in addition to their
genetic background, the environment to which the isolates were
exposed within the host affected their phenotypes. We hypothe-
size that the isolates with a lower mutation rate were in a slow-
growing state within the bioﬁlm, as compared with other isolates,
for which the selection might have happened in the peripheral
layers of the bioﬁlm, where they were growing closer to a
planktonic situation.
The delay in growth resumption and the lower growth rate we
observed by time-lapse analyses were most likely crucial for the
bacteria to survive within blood in presence of antibiotics and was
reﬂected by the long time to positivity of the blood cultures
(29–61 h). Furthermore, long time to positivity of the blood
cultures typically reﬂects a low number of bacteria. The clearance
of more than 99.99% of the bacteria under planktonic conditions
within 24 h by ciproﬂoxacin, highlighted the relevance of the
bioﬁlm for long-term survival within the patient.
We hypothesized that the long-term survival of the bacteria
was due to their localization within the bioﬁlm. We conﬁrmed
da
b e
c f
0.0 1.5 3.0 4.5 6.0 7.5
0
10
20
30
40
50
60
70
80
90
100
24
Time (h)
Pr
op
or
tio
n 
of
 s
ur
viv
or
s 
(%
) 1A
14G
16L
1A 1E  16N 1B 1C 1D  1F 16J 14G 16L 16O 16I 16H 16K16M
0
10
20
30
40
50
60
70
80
90
100
Pr
op
or
tio
n 
of
 s
ur
viv
or
s 
(%
)
****
3 h
24 h
Group I Group II
0.0
0.2
0.4
0.6
0.8
O
D 6
00
1A 14G 16L 1A 14G 16L 14G 16L
Biofilm (TSB) Biofilm (CIP) Biofilm (CIP/RIF)
Biofilm (CIP)
0.00
0.01
0.02
10
20
30
40
50
60
70
80
90
100
Ba
ct
er
ia
l s
ur
vi
va
l (%
)
1A
14G
16L
Growth to
stationnary phase
Fresh media
+ antibiotics Enumeration
Centrifuge
and rinse
Growth of
biofilm Fresh media
+ antibiotics Disrupt biofilm
Enumeration
OD measurment
Rinse
Supernatant
Planktonic (CIP) Biofilm (CIP/RIF)
1A 
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in vitro that the bioﬁlm produced by this speciﬁc clinical S. epi-
dermidis strain was not cleared by the antibiotics rifampicin and
ciproﬂoxacin, which are often given in clinics to treat bioﬁlm-
associated infections and which the patient was given at the time
of the break-through bacteremia.
Although we did not show a difference in survival, we observed
a thicker bioﬁlm remaining after antibiotic treatment in the two
late isolates 14G and 16L as compared with the early isolate 1A.
Dai et al. described increased extracellular bioﬁlm matrix pro-
duction in clinical S. epidermidis due to enhanced atlE-induced
autolysis38. Furthermore, cell lysis was described as relevant
source of the ica-independent bioﬁlm matrix composed of eDNA
and cytoplasmatic proteins in S. aureus40,41. The importance of
cell lysis for bioﬁlm formation might be an explanation why
isolate 1A formed a weaker bioﬁlm even though there were more
viable bacteria within both the treated and untreated bioﬁlm as
compared to 14G and 16L isolates (Supplementary Fig. 7).
Altogether, we conclude that the bacteremia despite the pre-
sence of antibiotics was most likely a consequence of bacterial
seeding from the bioﬁlm and survival of S. epidermidis in the
blood due to the observed tolerance phenotype.
In this study, we have focused on the genotypic basis of anti-
biotic tolerance. We observed an increase in lag time and decrease
in growth rate that affected the entire population, but this does
not rule out that subpopulations of persister cells contributed to
antibiotic treatment failure3,10. We did observe a subpopulation
of smaller colonies when bacteria were initially plated from the
pocket site infection and from the explanted pacemaker. Those
colonies could be an indication of phenotypic tolerance5. This
heterogeneity of colony size within the same isolate was lost when
the colonies were frozen and regrown.
To conclude, we showed for the ﬁrst time in-host adaptation of
S. epidermidis. We conﬁrmed in vitro that the bioﬁlm formed by
the S. epidermidis isolates was not cleared by the antibiotics used
in clinics. Even though a combination therapy consisting of
ciproﬂoxacin and rifampicin was applied, rifampicin resistance
evolved over time in this patient. We observed S. epidermidis
bacteremia despite fully effective antibiotic treatment highlighting
in vivo tolerance, which we conﬁrmed with in vitro studies. This
study conﬁrms the relevance of antibiotic tolerance, so far only
characterized in vitro, for chronic and difﬁcult-to-treat bacterial
infections as observed in this patient with an S. epidermidis
medical-device-associated bioﬁlm infection.
Methods
Ethical requirement. Informed patient consent was obtained (Cantonal ethic
commission Zurich).
Bacterial strains and growth conditions. Clinical S. epidermidis isolates (Table 1)
were isolated by sonication from the pacemaker as described before42 and char-
acterized at the Institute of Medical Microbiology of the University of Zurich. For
each clinical sample colonies with different morphology were archived if present,
otherwise only one colony was frozen. Species identiﬁcation was done by Microﬂex
LT mass spectrometer (Bruker Daltonik) as described before43.
The strains were stored in Lennox Broth (LB) supplemented with 20% glycerol at
−80 °C. Bacteria were grown on solid agar plates containing Tryptic Soy Broth (TSB,
BD) or columbia blood agar plates (BioMerieux) for ~40 h, if not indicated otherwise.
Overnight cultures (o/n) were inoculated from fresh plates in 5ml of TSB in 50 -ml
conical tubes and incubated for 18–20 h under shaking conditions (220 rpm) at
37 °C. Bacterial growth was measured by optical density at 600 nm (OD600) using a
WPA CO8000 Cell Density Meter (Biochrom, Berlin, Germany) or a SpectraMax i3
multi-mode microplate reader (Molecular Devices, San José, CA, USA).
Antibioticresistance evaluation. Disc diffusion assays were performed by the
Kirby–Bauer method according to the EUCAST guidelines using antibiotic disks
(SirscanDiscs™, i2a, (Montpellier, France)) for ampicillin, amoxicillin/clavulanic
acid, cefoxitin, vancomycin, teicoplanin, norﬂoxacin, ciproﬂoxacin, levoﬂoxacin,
moxiﬂoxacin, amikacin, gentamicin, tobramycin, tetracycline, erythromycin, clin-
damycin, sulfamethoxazole/trimethoprim, and rifampicin on Mueller–Hinton
plates. EUCAST breakpoints were used to assign a strain to be resistant or sus-
ceptible according to the inhibition zone diameter.
MICs were determined using broth microdilution in the Mueller–Hinton
medium according to EUCAST guidelines. MICs for ciproﬂoxacin (Bayer),
erythromycin (Sigma), and rifampicin (Labatec) were determined.
Field Emission Scanning Electron Microscopy. Field emission scanning electon
microscopy (FEM) was performed by the Imaging and Chemical Analysis
Laboratory of the Montana State University using a Zeiss SUPRA 55VP. After
explantation, one part of the electrode was immediately ﬁxed in 2.5% glutar-
aldehyde in 0.1 M cacodylate buffer. The electrode was rinsed four times with
distilled water for 15 min. Dehydration was performed with increasing con-
centration of ethanol, 20 min 25%, 20 min 50%, 20 min 75%, 30 min 95%, and
three times 1 h in 100% ethanol prior to crucial point drying.
Pulsed-ﬁeld gel electrophoresis. Pulsed-ﬁeld gel electrophoresis (PFGE) typing
of SmaI-digested genomic DNA was performed as recommended by Chung et al.44.
Brieﬂy, S. epidermidis o/n cultures were washed and resuspended in SE buffer
containing 2% low melt agarose to form plugs. Plugs were incubated with lysozyme
and mutanolysin in EC buffer overnight at 37 °C, with continous shaking. EC
buffer was aspired and EC buffer containing proteinase K was added overnight at
50–56 °C, with continous shaking. Plugs were washed and equilibrated in T10E10
buffer. Bacterial DNA containing plugs were restricted with SmaI. Digested DNA
was loaded on a 1% agarose gel and stained with ethidium bromide.
Quantitative bioﬁlm assays. S. epidermidis o/n cultures were diluted to an OD600
of 0.05 in 200 µl of the TSB medium supplemented with 0.5% glucose and grown
statically at 37 °C for 24 h in 96-well microplate (Greiner Bio-One). Supernatants
were discarded, bioﬁlms on the well bottom were washed twice with 100 µl of PBS
and resuspended in 200 µl of PBS. The biomass of the resuspended bioﬁlm was
determined by OD600 measurement. To determine matrix composition, proteinase
K (Omega Bio-Tek) at 0.1 mg/ml and DNase I (Roche) at 10 U/ml were added at
inoculation, and bioﬁlm formation was quantiﬁed after 24 h with crystal violet.
Therefore, wells were washed three times with 200 µl of PBS, dried at room tem-
perature before staining with 0.1% crystal violet for 30 min. After three wash steps
with distilled water, adhering dye was dissolved with 30% acetic acid, and the
absorption was measured at 570 nm. To determine the effect of antibiotics on
bioﬁlm integrity antibiotic media exceeding the MICs at least 40-fold were added
onto the 24 h pre-grown bioﬁlms (20 µg/ml ciproﬂoxacin or 20 µg/ml ciproﬂoxacin
and 12 µg/ml rifampicin in TSB 0.5% glucose). Biomass was determined by OD600
measurement of the resuspended bioﬁlm.
Growth curves. S. epidermidis o/n cultures were diluted to an OD600 of 0.02 in 200 µl
of the TSB medium in a 96-well plate and incubated in a VersaMax microplate
reader (Molecular Devices) for 20 h at 37 °C under constant shaking. The OD600
was measured every 10 min. The minimal doubling time was calculated from the
OD600 reads using 1 -h intervals. Student’s t test was used to determine the dif-
ference between the two groups and between two individual isolates.
Antibiotic persister assays. S. epidermidis o/n cultures were diluted to an OD600
of 0.05 which corresponded to about 2 × 107 CFUs/ml in the antibiotic media
(20 µg/ml ciproﬂoxacin), exceeding the MIC at least 40-fold. At inoculation and
after 3 and 24 h incubation for all isolates and additionally 1.5 h and 6 h for isolates
1A, 14G, and 16L in the antibiotic medium, bacteria were washed twice with PBS
before determination of CFUs by plating of serial dilutions.
Antibiotic exposure of bioﬁlms. Bioﬁlms were grown as described above for 24 h
in TSB 0.5% glucose. Supernatants were discarded, and bioﬁlms were washed twice
with 100 µl of PBS before 200 µl of antibiotic media exceeding the MICs at least 40-
fold were added onto the bioﬁlms (20 µg/ml ciproﬂoxacin or 20 µg/ml ciproﬂoxacin
and 12 µg/ml rifampicin in TSB 0.5% glucose). After 24 h incubation time, the
antibiotic medium was removed, and the bioﬁlms were washed twice and resus-
pended in 200 µl of PBS. CFUs were determined by plating of serial dilutions.
Quantitative hemolysis assay. Overnight cultures were grown in the Todd
Hewitt (TH) medium as recommended by Quiblier et al.45, adjusted to OD600 2,
centrifuged, sterile ﬁltered, and 100 µl were added to 100 µl of washed 5% sheep
blood erythrocytes in PBS obtained from deﬁbrinated sheep blood (Thermo
Fisher). After incubation at 37 °C for 30 min and at 4 °C for 30 min, hemoglobin
absorbance in the supernatant was measured at 415 nm.
Automated agar plate imaging. Overnight cultures or washed and resuspended
bioﬁlms were plated onto blood agar plates (Columbia+ 5% sheep blood, Bio-
merieux) and placed in a 37 °C incubator. Images were taken by Canon EOS 1200D
reﬂex cameras every 10 min for 48 h. Cameras were triggered by Arduino Uno
board and optocouplers. Colonies’ growth curves and radial growth were obtained
by analyzing the images with an in-house software. The following number of
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colonies were analyzed for stationary phase (1A: 75, 14G: 44, 16L: 66) and for
bioﬁlms (1A: 71, 14G: 65, 16L: 114).
Single-cell time-lapse microscopy. Bacteria were plated from frozen stock onto
blood agar plates (Columbia+ 5% sheep blood, Biomerieux). For inoculation, bacteria
were harvested from the plate into TSB or Dulbecco's Modiﬁed Eagle Medium
(DMEM) (4.5 g/l glucose, 10% FBS). The cultures were grown for 24 h and diluted to
OD 0.1 in their respective media. Diluted bacteria were streaked onto blood agar pads
containing Columbia media (BD) with 2% agar (bacteriological grade, BD) and 5%
sheep blood (Life Technologies). Agar pads were covered with cover glasses and
placed under the microscope at 37 °C. Bright ﬁeld images were taken every 30min no
later than 30min after initial inoculation at 100 × (U-FLN-Oil lens) with an auto-
mated Olympus IX81 inverted microscope. Up to 3000 positions per experiment were
recorded and the lag time of 90–189 bacteria was analyzed using the Cellsense soft-
ware. Time to cells’ ﬁrst division was manually determined using ImageJ software46.
Whole-genome sequencing and assembly. Total DNA of S. epidermidis clinical
isolates was extracted from a single colony inoculated in the liquid medium and
cultivated overnight using the DNeasy Blood & Tissue Kit (Qiagen), with an
additional enzymatic lysis step using lysozyme and lysostaphin. DNA was quality
checked with a Bioanalyzer (Agilent Technologies). Sequencing libraries were
constructed with a Nextera® XT kit (Illumina) for 13 strains and with a NEBNext®
Ultra™ kit (New England BioLabs) for isolates 16N and 16O, according to the
manufacturers’ recommendations. The sequencing was conducted on an Illumina
MiSeq machine with a read-length of 2 × 150 bp (2 × 300 bp for isolates 16N and
16O). The quality of the sequencing data was evaluated using FastQC (v0.11.5,
available at: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). CLC
Genomic Workbench 10 (CLC, Qiagen) was used for adapter and quality trim-
ming, resulting in 4’460’726 to 7’690’9632 reads for the Nextera XT library run. For
the NEB Next Ultra, 472’430 and 503’006 reads were left after trimming with CLC
for strains 16O and 16N, respectively. This corresponded to an approximated
average coverage of the genome of S. epidermidis of at least 250-fold and 50-fold,
respectively. De novo assemblies were generated using CLC and annotated by
RAST47, resulting in 51 to 72 contigs (average N50: 76’386.) for the isolates with
2 × 150 bp reads and in 38 and 42 contigs (N50: 125’473 and 133’023) for 16O and
16N, respectively.
Genetic variants calling. Detailed comparative analysis of single nucleotide
polymorphisms (SNPs) and short insertion and deletion (InDels) was performed
by mapping the reads to the reference genome of S. epidermidis RP62A (ATCC
35984, Supplementary Table 2) as well as by mapping the reads to the de novo
assembly of isolate 1A with CLC default settings (minimal frequency of 90% and a
minimal coverage of 10 reads). Non-speciﬁcally mapped reads were ignored. In all,
100% of the 1A de novo assembly was covered by all isolates, except for 1B and
16N which covered 98%. Mapping to the reference sequence of RP62A resulted in
an average coverage of 88%. This combined approach allowed us to cover almost
the whole sequence of the ST378 strains in the analysis, except for regions at the
start and end of contigs with insufﬁcient mapping quality. Furthermore, com-
parison with the reference allowed to dissect which variant corresponded to the
reference and which was an alternative allele in our isolates. The 13'658 identical
SNPs found in all isolates when compared with the reference (Supplementary
Data 1) were subtracted for further comparative analysis. The mutations unique to
one isolate or to a cluster of isolates are shown in Tables 2 and 3 (only non-
synonymous mutations) and Supplementary Table 3 (all mutations).
Pan-genome construction and phylogenetic analysis. De novo assemblies as
well as 14 published S. epidermidis assemblies (Supplementary Table 2) were
annotated with Prokka48. The output was used to construct a pan-genome with
Roary49, using a 100% cutoff (core genes are shared by all strains) and a 95%
default identity cutoff. This was done for all clinical isolates (ST59, ST88, and
ST378) together with the reference strains yielding in 1’767 core genes con-
catenated into a single pseudo-sequence of 1’665’907 nucleotides (nt) and indivi-
dually for the ST378 isolates only (2186 core genes, pseudo-sequence length
1’967’375 nt). The resulting alignments were used to build phylogenetic trees. The
maximum-likelihood trees were created with FastTree50 using the generalized
time-reversible (GTR) model of nucleotide evolution. The Bayesian evolutionary
analysis was performed in BEAST251 using an Hasegawa–Kishino–Yano (HKY)
substitution model, a relaxed clock model with lognormally distributed branch
rates and a birth–death-sampling tree prior52. The input was the alignment of the
SNPs extracted from the ST378 strains core-genes alignment with the SNP-sites
script (https://github.com/sanger-pathogens/snp-sites), gap-deleted and corrected
for base compositional bias. Bayesian Markov-chain Monte Carlo (MCMC) con-
vergence was conﬁrmed in Tracer53 and the summary tree was constructed using
TreeAnnotator. All trees were visualized with FigTree54.
Identiﬁcation of plasmid replicons and virulence factors. The presence of
plasmid replicons and virulence genes was investigated using the srst2 package,
with the default 90% coverage and 10% divergence cutoff55. The plasmid Finder
Database and the Virulence Factor Database (VFDB) were used, respectively.
Identiﬁcation of phages, resistance genes, and MLST. Phages were analyzed
using PHASTER56. Antibiotic resistance genes and multilocus sequence typing
(MLST) were determined using the tools of the Center for Genomic Epidemiology
RESﬁnder57,58.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Code availability
In-house software written for the time-lapse images analysis of this study is available at
GitHub (https://github.com/clementvulin/SCVLongLag).
Data availability
All raw sequence data have been submitted to the European Nucleotide Archive (ENA)
under project “PRJEB27742”. All the data produced for this study are available from the
corresponding author upon request or at “Figshare”.
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